SAN
DIEGO, Dec. 8, 2022 /PRNewswire/ -- Phanes
Therapeutics, Inc. (Phanes), a clinical stage biotech company
focused on innovative drug discovery and development in oncology,
today announced a clinical supply agreement with BeiGene, Ltd.
(NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes'
PT199, a differentiated anti-CD73 monoclonal antibody in
combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal
antibody in the Phase I clinical study (NCT05431270) for the
treatment of multiple advanced solid tumors.
![(PRNewsfoto/Phanes Therapeutics) (PRNewsfoto/Phanes Therapeutics)](https://mma.prnewswire.com/media/1180113/Phanes_logo__PNG_Logo.jpg)
"We are excited about the opportunity to evaluate PT199 in
combination with tislelizumab for the treatment of solid tumors,"
said Dr. Ming Wang, Founder and CEO
of Phanes. "PT199 is an anti-CD73 monoclonal antibody with a
differentiated mechanism of action to counter the
immunosuppressive tumor microenvironment in cancer patients. The
combination of PT199 with tislelizumab provides a new opportunity
to assess the strategy to enhance antitumor immune response in
patients with advanced or metastatic cancer refractory to previous
treatments."
The multi-center Phase I clinical trial of PT199 is evaluating
the safety, tolerability, pharmacokinetics, pharmacodynamics, and
preliminary efficacy of PT199, alone and in combination with
tislelizumab, a PD-1 inhibitor, in patients with locally advanced
or metastatic solid tumors that have progressed after all available
standard therapy or for which standard therapy has proven to be
ineffective, intolerable, or is considered inappropriate.
For more information on the study please visit
ClinicalTrials.gov (NCT05431270).
About PT199
PT199 is an anti-CD73 monoclonal antibody with a differentiated
mechanism of action and is designed to counter the
adenosine-mediated immunosuppressive tumor microenvironment (TME).
PT199 fully inhibits the enzyme activities of both soluble and
membrane-bound CD73, unlike some other anti-CD73 mAbs which exhibit
incomplete inhibition. Moreover, at higher concentrations, no loss
of inhibition or "hook effect" is observed with PT199. Hence, PT199
addresses the limitations of current CD73 inhibitors and is
expected to increase antitumor immune activation, and potentially
offer a new treatment option for cancer patients. PT199 is being
evaluated in a multi-center Phase I clinical trial in patients with
advanced solid tumors.
About Tislelizumab
Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody
specifically designed to minimize binding to Fc-gamma (Fcγ)
receptors on macrophages, helping to aid the body's immune cells to
detect and fight tumors. In pre-clinical studies, binding to Fcγ
receptors on macrophages has been shown to compromise the
anti-tumor activity of PD-1 antibodies through activation of
antibody-dependent macrophage-mediated killing of T effector cells.
Tislelizumab is the first investigational medicine from BeiGene's
immuno-oncology biologics program and is being evaluated in solid
tumor and hematologic malignancies, as monotherapy and in
combination.
About Phanes Therapeutics
Phanes Therapeutics, Inc. is a clinical stage biotech company
focused on innovative drug discovery and development in oncology.
Currently, it has three assets at clinical stage, including its
best-in-class monoclonal antibody (mAb) program, PT199, and two
first-in-class bispecific antibody programs, PT886 and PT217. Both
PT886 and PT217 have been granted orphan drug designation by FDA.
Its pipeline also includes humanized mAbs, biparatopics, and
single-chain variable fragments (scFvs) against multiple
tumor-associated antigens (TAAs) that are suitable for ADC and
CAR-T applications, respectively.
The company has built a strong pipeline by leveraging its
proprietary technology platforms: PACbodyTM,
SPECpairTM and ATACCbodyTM to
develop novel biologics that address high unmet medical needs in
cancer. PACbodyTM is a proprietary approach for
constructing bispecific antibodies without using protein
engineering so that the antibody molecules maintain native
structures with superb CMC characteristics,
SPECpairTM allows mAb-like manufacturability of
bispecific antibodies with native IgG-like structures, and
ATACCbodyTM is a technology for targeting solid
tumors using immuno-oncology molecules with modulated activities
designed to minimize the risk of cytokine release syndrome.
For more information about Phanes Therapeutics, please visit
www.phanesthera.com.
For business development or media inquiries please contact
bd@phanestx.com or media@phanestx.com, respectively.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-clinical-supply-agreement-with-beigene-to-evaluate-pt199-in-combination-with-tislelizumab-301698698.html
SOURCE Phanes Therapeutics